Calluna Pharma
PrivateLast Round
Series A
Jan 23, 2024
Total Funding Raised
$81.3M
Momentum Score
50 /100
Company Overview
Calluna Pharma is a clinical-stage biotechnology company developing a pipeline of selective antibodies to treat inflammatory and fibrotic diseases by targeting the innate immune system.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Calluna Pharma Comps
Public and private peers based on sector, stage, and business model.
Calluna Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 23, 2024 |
Key People
Founding team and executive leadership
Calluna Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Investinor | Series A |
| Sarsia | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 16, 2025
Gijs van den Brink appointed as independent director.
- Apr 29, 2025
Three posters to be presented at the 2025 ATS International Conference.
Calluna Pharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Calluna Pharma's valuation, stock price, and market status.
